{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T01:00:43Z","timestamp":1794186043708,"version":"4.8.0"},"reference-count":59,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K21590"],"award-info":[{"award-number":["JP19K21590"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP20H00563"],"award-info":[{"award-number":["JP20H00563"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020964","name":"Fusion Oriented REsearch for disruptive Science and Technology","doi-asserted-by":"publisher","award":["JPMJFR205J"],"award-info":[{"award-number":["JPMJFR205J"]}],"id":[{"id":"10.13039\/501100020964","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>Rebamipide has been widely co-prescribed with non-steroidal anti-inflammatory drugs (NSAIDs) in Japan for decades. This study aimed to evaluate the effectiveness of rebamipide in preventing upper gastrointestinal bleeding in new users of NSAIDs without risk factors of NSAID-induced ulcers other than age.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>A nested case-control study was conducted using medical claims data of 1.66 million inhabitants of 17 municipalities participating in Japan\u2019s Longevity Improvement &amp; Fair Evidence study. The cohort entry (t<jats:sub>0<\/jats:sub>) corresponded to a new user of NSAIDs for osteoarthritis or low back pain. Patients with risk factors of NSAID-induced ulcers other than age were excluded. Cases were defined as patients who underwent gastroscopy for upper gastrointestinal bleeding (occurrence date was defined as index date). A maximum of 10 controls were selected from non-cases at the index date of each case by matching sex, age, follow-up time, and type and dosage of NSAIDs. Exposure to rebamipide was defined as prescription status from t<jats:sub>0<\/jats:sub> to index date: Non-user (rebamipide was not co-prescribed during the follow-up period), Continuous-user (rebamipide was co-prescribed from t<jats:sub>0<\/jats:sub> with the same number of tablets as NSAIDs), and Irregular-user (neither Non-user nor Continuous-user). Conditional logistic regression analysis was conducted to estimate each category\u2019s odds ratio compared to non-users.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Findings<\/jats:title>\n<jats:p>Of 67,561 individuals who met the inclusion criteria, 215 cases and 1,516 controls were selected. Compared with that of Non-users, the odds ratios and 95% confidence interval were 0.65 (0.44\u20130.96) for Continuous-users and 2.57 (1.73\u20133.81) for Irregular-users.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Continuous co-prescription of rebamipide significantly reduced the risk of upper gastrointestinal bleeding in an Asian cohort of new users of NSAIDs with osteoarthritis or low back pain without risk factors other than age.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0305320","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:22:47Z","timestamp":1718130167000},"page":"e0305320","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":3,"title":["Continuous co-prescription of rebamipide prevents upper gastrointestinal bleeding in NSAID use for orthopaedic conditions: A nested case-control study using the LIFE Study database"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2378-1917","authenticated-orcid":true,"given":"Satoshi","family":"Yamate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieko","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1120-1548","authenticated-orcid":true,"given":"Haruhisa","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6302-2539","authenticated-orcid":true,"given":"Satoshi","family":"Hamai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuharu","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,11]]},"reference":[{"issue":"Suppl 1","key":"pone.0305320.ref001","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1007\/s10620-005-2800-9","article-title":"15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications","volume":"50","author":"T Arakawa","year":"2005","journal-title":"Dig Dis Sci"},{"key":"pone.0305320.ref002","author":"Ministry of Health, Labour and Welfare, Government of Japan","journal-title":"8th NDB Open Data"},{"issue":"9","key":"pone.0305320.ref003","first-page":"5S","article-title":"Rebamipide: overview of its mechanisms of action and efficacy in mucosal protection and ulcer healing","volume":"43","author":"T Arakawa","year":"1998","journal-title":"Dig Dis Sci"},{"issue":"7","key":"pone.0305320.ref004","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1007\/s10620-008-0507-4","article-title":"Rebamipide, a cytoprotective drug, increases gastric mucus secretion in human: evaluations with endoscopic gastrin test","volume":"54","author":"K Iijima","year":"2009","journal-title":"Dig Dis Sci"},{"issue":"6","key":"pone.0305320.ref005","doi-asserted-by":"crossref","first-page":"841","DOI":"10.5009\/gnl20338","article-title":"Efficacy and safety of rebamipide versus its new formulation, AD-203, in patients with erosive gastritis: A randomized, double-blind, active control, noninferiority, multicenter, phase 3 study","volume":"15","author":"GH Kim","year":"2021","journal-title":"Gut Liver"},{"key":"pone.0305320.ref006","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.2147\/IJGM.S353098","article-title":"Rebamipide as a potential alternative gastroprotective agent to proton pump inhibitor in elderly chronic non-steroidal anti-inflammatory drug users without risk factors.","volume":"15","author":"MY Lee","year":"2022","journal-title":"Int J Gen Med"},{"issue":"4","key":"pone.0305320.ref007","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00535-021-01769-0","article-title":"Evidence-based clinical practice guidelines for peptic ulcer disease 2020","volume":"56","author":"T Kamada","year":"2021","journal-title":"J Gastroenterol"},{"issue":"4","key":"pone.0305320.ref008","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/gutjnl-2019-319300","article-title":"Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE\/APLAR\/APSDE\/APSH\/APSN\/PoA recommendations","volume":"69","author":"CC Szeto","year":"2020","journal-title":"Gut"},{"issue":"26","key":"pone.0305320.ref009","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa021907","article-title":"Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis","volume":"347","author":"FK Chan","year":"2002","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0305320.ref010","first-page":"728","article-title":"Guidelines for prevention of NSAID-related ulcer complications","volume":"104","author":"FL Lanza","year":"2009","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"pone.0305320.ref011","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1572-0241.2006.00499.x","article-title":"Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors","volume":"101","author":"JM Scheiman","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"pone.0305320.ref012","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1053\/j.gastro.2011.03.049","article-title":"Acid suppressants reduce risk of gastrointestinal bleeding in patients on antithrombotic or anti-inflammatory therapy","volume":"141","author":"KJ Lin","year":"2011","journal-title":"Gastroenterology"},{"issue":"3","key":"pone.0305320.ref013","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1572-0241.2006.01062.x","article-title":"Effect of antisecretory drugs and nitrates on the risk of ulcer bleeding associated with non-steroidal anti-inflammatory drugs, antiplatelet agents, and anticoagulants","volume":"102","author":"A Lanas","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"pone.0305320.ref014","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1177\/2042098617715381","article-title":"Adverse effects of proton-pump inhibitor use in older adults: a review of the evidence","volume":"8","author":"ML Maes","year":"2017","journal-title":"Ther Adv Drug Saf"},{"issue":"1","key":"pone.0305320.ref015","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1038\/s41598-017-05552-1","article-title":"Proton pump inhibitors and the risk for fracture at specific sites: data mining of the FDA Adverse Event Reporting System.","volume":"7","author":"L Wang","year":"2017","journal-title":"Sci Rep."},{"issue":"4","key":"pone.0305320.ref016","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/17453674.2021.1920687","article-title":"Proton-pump inhibitors are associated with increased risk of prosthetic joint infection in patients with total hip arthroplasty: a case-cohort study.","volume":"92","author":"MM Bruin","year":"2021","journal-title":"Acta Orthop"},{"issue":"1","key":"pone.0305320.ref017","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1136\/gutjnl-2020-322248","article-title":"Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching","volume":"70","author":"SW Lee","year":"2021","journal-title":"Gut"},{"issue":"1","key":"pone.0305320.ref018","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/j.gastro.2017.04.047","article-title":"Complications of proton pump inhibitor therapy","volume":"153","author":"MF Vaezi","year":"2017","journal-title":"Gastroenterology"},{"issue":"7","key":"pone.0305320.ref019","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1136\/gutjnl-2021-325701","article-title":"Proton-pump inhibitor use is not associated with severe COVID-19-related outcomes: a propensity score-weighted analysis of a national veteran cohort","volume":"71","author":"S Shah","year":"2022","journal-title":"Gut"},{"issue":"7","key":"pone.0305320.ref020","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1053\/j.gastro.2021.02.028","article-title":"Lack of consistent associations between pharmacologic gastric acid suppression and adverse outcomes in patients with coronavirus disease 2019: meta-analysis of observational studies","volume":"160","author":"F Kamal","year":"2021","journal-title":"Gastroenterology"},{"issue":"1","key":"pone.0305320.ref021","doi-asserted-by":"crossref","first-page":"7839","DOI":"10.1038\/s41598-022-11505-0","article-title":"Frequently reported adverse events of rebamipide compared to other drugs for peptic ulcer and gastroesophageal reflux disease.","volume":"12","author":"E Jang","year":"2022","journal-title":"Sci Rep"},{"key":"pone.0305320.ref022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1741-7015-9-38","article-title":"Prescription patterns and appropriateness of NSAID therapy according to gastrointestinal risk and cardiovascular history in patients with diagnoses of osteoarthritis.","volume":"9","author":"A Lanas","year":"2011","journal-title":"BMC Med"},{"issue":"2","key":"pone.0305320.ref023","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/MLR.0000000000001244","article-title":"Evaluation and treatment patterns of new low back pain episodes for elderly adults in the United States, 2011\u20132014.","volume":"58","author":"DP Ly","year":"2020","journal-title":"Med Care"},{"issue":"1","key":"pone.0305320.ref024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1056\/NEJMcp1903768","article-title":"Osteoarthritis of the knee","volume":"384","author":"L. Sharma","year":"2021","journal-title":"N Engl J Med"},{"issue":"24","key":"pone.0305320.ref025","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.2106\/JBJS.21.01547","article-title":"Multiple imputation to salvage partial respondents: analysis of the forgotten joint Score-12 after total hip arthroplasty","volume":"104","author":"S Yamate","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"pone.0305320.ref026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jjoisr.2022.12.004","article-title":"Clinical evaluation of hip joint diseases: total hip arthroplasty to support patients\u2019 quality of life.","volume":"1","author":"S Yamate","year":"2023","journal-title":"J Joint Surg Res"},{"issue":"2","key":"pone.0305320.ref027","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/cpt.2263","article-title":"Nested case-control study utilizing MID-NET\u00ae on thrombocytopenia associated with pegfilgrastim in patients treated with antineoplastic agents","volume":"110","author":"K Kajiyama","year":"2021","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"pone.0305320.ref028","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1002\/pds.3699","article-title":"Antipsychotic drugs and risk of idiopathic venous thromboembolism: a nested case-control study using the CPRD.","volume":"23","author":"C Ishiguro","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"pone.0305320.ref029","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1017\/CBO9781139094757.010","volume-title":"Nested case-control studies.","author":"RH Keogh","year":"2014"},{"issue":"9596","key":"pone.0305320.ref030","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"E von Elm","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"pone.0305320.ref031","doi-asserted-by":"crossref","first-page":"e0125620","DOI":"10.1371\/journal.pone.0125620","article-title":"The REporting of studies conducted using observational routinely collected health data [record] [statement].","volume":"10","author":"SG Nicholls","year":"2015","journal-title":"PLOS ONE."},{"issue":"8","key":"pone.0305320.ref032","doi-asserted-by":"crossref","first-page":"428","DOI":"10.2188\/jea.JE20210513","article-title":"The Longevity Improvement & Fair Evidence (LIFE) study: overview of the study design and baseline participant profile.","volume":"33","author":"H Fukuda","year":"2023","journal-title":"J Epidemiol"},{"issue":"2","key":"pone.0305320.ref033","doi-asserted-by":"crossref","first-page":"807","DOI":"10.3233\/JAD-201508","article-title":"Medical care and long-term care expenditures attributable to Alzheimer\u2019s disease onset: results from the LIFE study","volume":"84","author":"H Fukuda","year":"2021","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"pone.0305320.ref034","doi-asserted-by":"crossref","first-page":"e100802","DOI":"10.1136\/gpsych-2022-100802","article-title":"Acute and delayed psychiatric sequelae among patients hospitalised with COVID-19: a cohort study using LIFE study data.","volume":"35","author":"F Murata","year":"2022","journal-title":"Gen Psychiatr"},{"key":"pone.0305320.ref035","unstructured":"e-Stat. Japanese Government Statistics. Available from: https:\/\/www.e-stat.go.jp\/stat-search\/files?stat_infid=000040032780."},{"issue":"11","key":"pone.0305320.ref036","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1007\/s10620-008-0255-5","article-title":"An open-labeled study of rebamipide treatment in chronic gastritis patients with dyspeptic symptoms refractory to proton pump inhibitors","volume":"53","author":"T Chitapanarux","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"10","key":"pone.0305320.ref037","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1007\/s40261-015-0329-z","article-title":"Effect of rebamipide on the premalignant progression of chronic gastritis: A randomized controlled study.","volume":"35","author":"X Han","year":"2015","journal-title":"Clin Drug Investig"},{"issue":"8","key":"pone.0305320.ref038","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s00535-007-2076-2","article-title":"Rebamipide, a gastro-protective and anti-inflammatory drug, promotes gastric ulcer healing following eradication therapy for Helicobacter pylori in a Japanese population: a randomized, double-blind, placebo-controlled trial","volume":"42","author":"A Terano","year":"2007","journal-title":"J Gastroenterol"},{"issue":"7","key":"pone.0305320.ref039","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2036.2008.03808.x","article-title":"Clinical trial: the incidence and early mortality after peptic ulcer perforation, and the use of low-dose aspirin and non-steroidal anti-inflammatory drugs","volume":"28","author":"AS Taha","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"pone.0305320.ref040","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality.","volume":"57","author":"V Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"11","key":"pone.0305320.ref041","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1007\/s10620-007-0180-z","article-title":"Anti-inflammatory effects of rebamipide according to Helicobacter pylori status in patients with chronic erosive gastritis: a randomized sucralfate-controlled multicenter trial in China-STARS study","volume":"53","author":"Y Du","year":"2008","journal-title":"Dig Dis Sci"},{"issue":"4","key":"pone.0305320.ref042","doi-asserted-by":"crossref","first-page":"371","DOI":"10.5009\/gnl.2014.8.4.371","article-title":"Preventive efficacy and safety of rebamipide in non-steroidal anti-inflammatory drug-induced mucosal toxicity","volume":"8","author":"JH Kim","year":"2014","journal-title":"Gut Liver"},{"issue":"1","key":"pone.0305320.ref043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s00535-010-0332-3","article-title":"Rebamipide has the potential to reduce the intensity of NSAID-induced small intestinal injury: a double-blind, randomized, controlled trial evaluated by capsule endoscopy","volume":"46","author":"S Fujimori","year":"2011","journal-title":"J Gastroenterol"},{"issue":"2","key":"pone.0305320.ref044","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/1751-2980.13075","article-title":"The risk of pulmonary adverse drug reactions of rebamipide and other drugs for acid-related diseases: An analysis of the national pharmacovigilance database in South Korea.","volume":"23","author":"BR Yang","year":"2022","journal-title":"J Dig Dis"},{"issue":"1","key":"pone.0305320.ref045","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1038\/s41598-022-06611-y","article-title":"Preventive effect of rebamipide on NSAID-induced lower gastrointestinal tract injury using FAERS and JADER.","volume":"12","author":"T Imai","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"pone.0305320.ref046","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00535-009-0157-0","article-title":"Clinical trial: rebamipide promotes gastric ulcer healing by proton pump inhibitor after endoscopic submucosal dissection\u2014a randomized controlled study","volume":"45","author":"T Kato","year":"2010","journal-title":"J Gastroenterol"},{"issue":"3","key":"pone.0305320.ref047","first-page":"216","article-title":"Efficacy of rebamipide for low-dose aspirin-related gastrointestinal symptoms","volume":"51","author":"K Mizukami","year":"2012","journal-title":"J Clin Biochem Nutr"},{"issue":"2","key":"pone.0305320.ref048","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/jbmr.4754","article-title":"PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort","volume":"38","author":"X Zhang","year":"2023","journal-title":"J Bone Miner Res"},{"key":"pone.0305320.ref049","author":"US Food and Drug Administration","journal-title":"FDA Drug Safety Communication: possible increased risk of fractures of the hip, w, and spine with the use of proton pump inhibitors"},{"issue":"7","key":"pone.0305320.ref050","first-page":"243","article-title":"Adverse event profiles of hypomagnesemia caused by proton pump inhibitors using the Japanese Adverse Drug Event Report (JADER) Database.","volume":"77","author":"K Yamashiro","year":"2022","journal-title":"Pharmazie"},{"issue":"7","key":"pone.0305320.ref051","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1177\/1060028018760569","article-title":"The Risk of Community-Acquired Enteric Infection in Proton Pump Inhibitor Therapy: Systematic Review and Meta-analysis","volume":"52","author":"RA Hafiz","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"11\u201312","key":"pone.0305320.ref052","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1111\/j.1365-2036.2011.04874.x","article-title":"Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection","volume":"34","author":"C Bavishi","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0305320.ref053","article-title":"Life Course Epidemiology of Hip Osteoarthritis in Japan: A Multicenter, Cross-Sectional Study.","author":"T Sato","year":"2024","journal-title":"J Bone Joint Surg Am"},{"issue":"19","key":"pone.0305320.ref054","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.2106\/JBJS.21.01415","article-title":"Costs of nonoperative procedures for knee osteoarthritis in the year prior to primary total knee arthroplasty","volume":"104","author":"DZ Nin","year":"2022","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"pone.0305320.ref055","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13018-021-02298-5","article-title":"Contemporary indications for first-time revision surgery after primary cementless total hip arthroplasty with emphasis on early failures","volume":"16","author":"G Motomura","year":"2021","journal-title":"J Orthop Surg Res"},{"issue":"9","key":"pone.0305320.ref056","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1007\/s00228-014-1713-y","article-title":"Comparison of acid inhibition with standard dosages of proton pump inhibitors in relation to CYP2C19 genotype in Japanese","volume":"70","author":"M Sugimoto","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"pone.0305320.ref057","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s00535-014-1031-2","article-title":"Time series analysis of gastric acid secretion over a 20-year period in normal Japanese men","volume":"50","author":"K Iijima","year":"2015","journal-title":"J Gastroenterol"},{"key":"pone.0305320.ref058","doi-asserted-by":"crossref","first-page":"11136","DOI":"10.3389\/jpps.2023.11136","article-title":"The role of CYP2C9*2, CYP2C9*3 and VKORC1-1639 variants on the susceptibility of upper gastrointestinal bleeding: A full case-control study.","volume":"26","author":"M Forgerini","year":"2023","journal-title":"J Pharm Pharm Sci."},{"issue":"1","key":"pone.0305320.ref059","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40246-023-00461-z","article-title":"Global distribution of functionally important CYP2C9 alleles and their inferred metabolic consequences","volume":"17","author":"Y Zhou","year":"2023","journal-title":"Hum Genomics"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305320","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T18:23:27Z","timestamp":1718130207000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305320"}},"subtitle":[],"editor":[{"given":"Mahmoud","family":"Kandeel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,11]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305320","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,11]]}}}